AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6370581 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% aqueous sodium lauryl sulfate (SLS) solution applied for 24 hours
Number of subjects: 36
Study 6370581 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% aqueous sodium lauryl sulfate (SLS) solution applied for 24 hours
Number of subjects: 36
Study 6370581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aqueous sodium lauryl sulfate (SLS) solution applied for two successive 24-hour applications
Number of subjects: 36
Study 6370581 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% aqueous sodium lauryl sulfate (SLS) solution applied for two successive 24-hour applications
Number of subjects: 36
Study 30719580 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid
Number of subjects: 3229
Study 30719580 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 3229
Study 29953013 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansankachimpihange (YKSCH)
Number of subjects: 34
Study 29953013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 27141834 — intervention group
Group type: EXPERIMENTAL
Intervention: LINC intervention
Number of subjects: 349
Study 27141834 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 349
Study 24973361 — intervention group
Group type: EXPERIMENTAL
Intervention: ASXL2 mutations in t(8;21) AML patients
Number of subjects: 110
Study 24973361 — intervention group
Group type: EXPERIMENTAL
Intervention: ASXL1 mutations in t(8;21) AML patients
Number of subjects: 110
Study 24973361 — intervention group
Group type: COMPARATOR
Intervention: ASXL1/2 wild-type counterparts
Number of subjects: 110
Study 24973361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival comparison
Number of subjects: 110
Study 23079354 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in initiation to learning reading (experimental group)
Number of subjects: 144
Study 23079354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 144
Study 21144223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 4 weeks
Number of subjects: 315
Study 21144223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 315
Study 21144223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 17685689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training (Z1)
Number of subjects: 12
Study 17685689 — intervention group
Group type: COMPARATOR
Intervention: Moderately high-intensity training (Z2)
Number of subjects: 12
Study 15379010 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alias
Number of subjects: 540
Study 15379010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 aliases
Number of subjects: 540
Study 15379010 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 aliases
Number of subjects: 540
Study 15379010 — intervention group
Group type: COMPARATOR
Intervention: No alias information
Number of subjects: 540
Study 15379010 — intervention group
Group type: EXPERIMENTAL
Intervention: All 9 aliases with relationship information
Number of subjects: 540
Study 15379010 — intervention group
Group type: COMPARATOR
Intervention: All 9 aliases without relationship information
Number of subjects: 540
Study 11380067 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg dose of metronidazole
Number of subjects: 24
Study 9685816 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 2656
Study 9685816 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol
Number of subjects: 2656
Study 9685816 — intervention group
Group type: COMPARATOR
Intervention: ionic CMs
Number of subjects: 2656
Study 9685816 — intervention group
Group type: COMPARATOR
Intervention: non-ionic CMs
Number of subjects: 2656
Study 7978086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CB) for ASPs
Number of subjects: 149
Study 7978086 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship Enhancement Treatment for ASPs
Number of subjects: 149
Study 7978086 — intervention group
Group type: COMPARATOR
Intervention: Non-ASPs treated with any method
Number of subjects: 149
Study 2791543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) - different qualities
Number of subjects: 0
Study 2791543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) - high purity
Number of subjects: 0
Study 7767 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 2 (3.0 gm of protein per 100 ml, 60:40)
Number of subjects: 106
Study 7767 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 4 (3.0 gm of protein per 100 ml, 18:82)
Number of subjects: 106
Study 7767 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 1 (1.5 gm of protein per 100 ml, 60:40)
Number of subjects: 106
Study 7767 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 3 (1.5 gm of protein per 100 ml, 18:82)
Number of subjects: 106
Study 7767 — intervention group
Group type: COMPARATOR
Intervention: Banked human milk (BM)
Number of subjects: 106
Study 7767 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein‐predominant formulas (F3, F4)
Number of subjects: 106
Study 7767 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein‐predominant formulas (F1, F2)
Number of subjects: 106
Study 30658003 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical positioning software
Number of subjects: 200
Study 30658003 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy (Control)
Number of subjects: 200
Study 28902012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Voriconazole (VCZ) 200 mg twice a day
Number of subjects: 50
Study 28902012 — intervention group
Group type: COMPARATOR
Intervention: Oral Ketoconazole (KCZ) 200 mg twice a day
Number of subjects: 50
Study 26637828 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls experiencing IPV
Number of subjects: 0
Study 26637828 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys perpetrating IPV
Number of subjects: 0
Study 25066019 — intervention group
Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity (SBS-PA)
Number of subjects: 10
Study 25066019 — intervention group
Group type: COMPARATOR
Intervention: Unstructured playtime (UPA)
Number of subjects: 10
Study 25066019 — intervention group
Group type: EXPERIMENTAL
Intervention: SBS-PA and UPA
Number of subjects: 10
Study 22825948 — intervention group
Group type: EXPERIMENTAL
Intervention: LVFWR group (49 patients)
Number of subjects: 270
Study 22825948 — intervention group
Group type: COMPARATOR
Intervention: Non-LVFWR group (221 patients)
Number of subjects: 270
Study 19417866 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% carbamide peroxide with 5% potassium nitrate (treatment A)
Number of subjects: 40
Study 19417866 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% carbamide peroxide without potassium nitrate (treatment B)
Number of subjects: 40
Study 17690311 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decompressive craniectomy
Number of subjects: 38
Study 17690311 — intervention group
Group type: COMPARATOR
Intervention: No surgery (medical therapy only)
Number of subjects: 38
Study 15031622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sono-guided endometrial biopsy (SH-EB) using a 3.1-mm ultrasound-guided Bernard catheter
Number of subjects: 105
Study 15031622 — intervention group
Group type: COMPARATOR
Intervention: Endometrial biopsy after hysteroscopy (HSC-EB) using a Cornier Pipelle
Number of subjects: 105
Study 15031622 — intervention group
Group type: COMPARATOR
Intervention: Comparison of endometrial thickness
Number of subjects: 105
Study 11579707 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (starting at 7.5 mg/week, max 20 mg/week)
Number of subjects: 21
Study 11579707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9701736 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous suprapubic transvesical route (STR)
Number of subjects: 37
Study 9701736 — intervention group
Group type: COMPARATOR
Intervention: Transperineal route (TPR)
Number of subjects: 37
Study 9701736 — intervention group
Group type: EXPERIMENTAL
Intervention: STR
Number of subjects: 37
Study 9701736 — intervention group
Group type: COMPARATOR
Intervention: TPR
Number of subjects: 37
Study 7493231 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 82
Study 7493231 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 82
Study 7493231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure regulation
Number of subjects: 82
Study 7493231 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine vs laser trabeculoplasty
Number of subjects: 82
Study 1965007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 40
Study 1965007 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 40
Study 1965007 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin-B
Number of subjects: 40
Study 1965007 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 40
Study 759142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandovac 1000
Number of subjects: 104
Study 759142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandovac 2000
Number of subjects: 104
Study 31724377 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD and PTG assessment using geographic information systems analyses
Number of subjects: 171
Study 31724377 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic information systems analyses
Number of subjects: 171
Study 27647837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric, low-glycaemic, low-saturated fat diet and physical activity recommendations
Number of subjects: 191
Study 27647837 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (lifestyle advice regarding healthy nutrition and exercise)
Number of subjects: 191
Study 27647837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (adherent women)
Number of subjects: 191
Study 27647837 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 191
Study 26166166 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (OctLAR) 40 mg monthly
Number of subjects: 28
Study 26166166 — intervention group
Group type: COMPARATOR
Intervention: Off therapy
Number of subjects: 28
Study 26166166 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (OctLAR)
Number of subjects: 28
Study 24814320 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor therapy sessions provided by professional 'ElderClowns' (9 to 12 weekly sessions)
Number of subjects: 398
Study 24814320 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 398
Study 23214253 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 84
Study 23214253 — intervention group
Group type: COMPARATOR
Intervention: Control (antibiotics plus hemostatics with usual wound care)
Number of subjects: 84
Study 19107591 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 75
Study 19107591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 19107591 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD (regardless of medication)
Number of subjects: 75
Study 17785752 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTrans autologous retransfusion system
Number of subjects: 158
Study 17785752 — intervention group
Group type: COMPARATOR
Intervention: Two vacuum drains
Number of subjects: 158
Study 15177825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-exposed group
Number of subjects: 40
Study 15177825 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 12271412 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium iodide (KI) 100 mg per day starting 2 days before (131)I-lipiodol administration and continuing until 2 weeks after therapy; n=31
Number of subjects: 68
Study 12271412 — intervention group
Group type: COMPARATOR
Intervention: No potassium iodide (non-KI group); n=37
Number of subjects: 68
Study 9805727 — intervention group
Group type: EXPERIMENTAL
Intervention: New programme of antenatal care
Number of subjects: 53
Study 9805727 — intervention group
Group type: COMPARATOR
Intervention: Current programme in use
Number of subjects: 53
Study 7715639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 299
Study 7715639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 2651248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosulepin (Idom) 75 mg daily in the evening
Number of subjects: 48
Study 2651248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 520386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine‐Sandoz (ergot alkaloids)
Number of subjects: 60
Study 520386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31840388 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral antiviral use pre- and post-treatment
Number of subjects: 58
Study 31840388 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment sun protection
Number of subjects: 58
Study 30421864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal intervention with meal replacements
Number of subjects: 264
Study 30421864 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study 28399483 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) intervention to incentivize safe sex
Number of subjects: 20
Study 26331550 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (120 μg/kg)
Number of subjects: 7
Study 26331550 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 23935959 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 26
Study 23935959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22609501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 25 microgram/kg/min
Number of subjects: 120
Study 22609501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 50 microgram/kg/min
Number of subjects: 120
Study 22609501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 75 microgram/kg/min
Number of subjects: 120
Study 22609501 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 19146991 — intervention group
Group type: EXPERIMENTAL
Intervention: Plausible value imputation (PVI)
Number of subjects: 0
Study 19146991 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent marginal maximum likelihood (MML)
Number of subjects: 0
Study 19146991 — intervention group
Group type: COMPARATOR
Intervention: Limited information two-step marginal maximum likelihood method
Number of subjects: 0
Study 16710252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of perindopril (2 mg) and indapamide (0.625 mg)
Number of subjects: 72
Study 16710252 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with enalapril (10 mg)
Number of subjects: 72
Study 16968506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation with BIS visible (Phase 1)
Number of subjects: 102
Study 16968506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation with BIS visible (Phase 2)
Number of subjects: 102
Study 16968506 — intervention group
Group type: COMPARATOR
Intervention: Control group (Phase 1)
Number of subjects: 102
Study 16968506 — intervention group
Group type: COMPARATOR
Intervention: Control group (Phase 2)
Number of subjects: 102
Study 14567499 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-receptor blocker (ARB: valsartan)
Number of subjects: 0
Study 14567499 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I: temocapril)
Number of subjects: 0
Study 14567499 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting Ca antagonists (L- and N-type Ca channel blocker: cilnidipine)
Number of subjects: 0
Study 14567499 — intervention group
Group type: EXPERIMENTAL
Intervention: L-type Ca channel blocker (nifedipine CR)
Number of subjects: 0
Study 10423075 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine, with possible addition of enalapril and hydrochlorothiazide)
Number of subjects: 4695
Study 8655368 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (BEC regimen)
Number of subjects: 339
Study 8655368 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 339
Study 1796409 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 12
Study 1796409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6351587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tyrosine (7.5 g/day)
Number of subjects: 0
Study 6351587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tryptophan (3 g/day)
Number of subjects: 0
Study 30314504 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturising oil
Number of subjects: 20
Study 30314504 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study 28719062 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR interactive model
Number of subjects: 66
Study 28719062 — intervention group
Group type: COMPARATOR
Intervention: Online textbooks
Number of subjects: 66
Study 25098596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) combined with chest physical therapy (CPT)
Number of subjects: 20
Study 25098596 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard chest physical therapy (CPT)
Number of subjects: 20
Study 23177921 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video-game based (IVGB) training for 6 weeks
Number of subjects: 30
Study 23177921 — intervention group
Group type: COMPARATOR
Intervention: No intervention (first 6 weeks) followed by IVGB training (next 6 weeks)
Number of subjects: 30
Study 22321885 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (drug A)
Number of subjects: 155
Study 22321885 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron (drug B)
Number of subjects: 155
Study 18192922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (RAPA)
Number of subjects: 18
Study 18192922 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Number of subjects: 18
Study 16441782 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival plaque samples from peri-implant pockets
Number of subjects: 42
Study 16441782 — intervention group
Group type: COMPARATOR
Intervention: Cultural techniques
Number of subjects: 42
Study 15110922 — intervention group
Group type: EXPERIMENTAL
Intervention: PMDD patients during the follicular phase
Number of subjects: 28
Study 15110922 — intervention group
Group type: COMPARATOR
Intervention: Symptom-free controls during the follicular phase
Number of subjects: 28
Study 11122727 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 0
Study 11122727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9315523 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and low-cholesterol diet
Number of subjects: 72
Study 8233296 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and simultaneous carboplatin (60 or 70 mg/m2 from days 1‐5 and 29‐33) with a fractionation of 5 x 2 Gy/week up to a dose of 50 Gy.
Number of subjects: 100
Study 8233296 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiotherapy (2 x 1.6 Gy/day, 5 days per week: total dose, 64‐67.2 Gy) and simultaneous intravenous carboplatin (60 mg/m2, days 1‐5 and 29‐33).
Number of subjects: 100
Study 8233296 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy with carboplatin (not detailed in the abstract).
Number of subjects: 100
Study 8233296 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated accelerated irradiation with carboplatin (not detailed in the abstract).
Number of subjects: 100
Study 3518183 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic carbenicillin indanyl sodium
Number of subjects: 30
Study 3518183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29412521 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchially administered adipose-derived stem cells (ADSCs)
Number of subjects: 14
Study 26483047 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab (wt-B)
Number of subjects: 233
Study 26483047 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab + erlotinib (wt-BE)
Number of subjects: 233
Study 26483047 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab (mut-B)
Number of subjects: 233
Study 26483047 — intervention group
Group type: COMPARATOR
Intervention: metronomic capecitabine (mut-C)
Number of subjects: 233
Study 25123600 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 200 mg
Number of subjects: 154
Study 25123600 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 400 mg
Number of subjects: 154
Study 25123600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 21553144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (DMIE program)
Number of subjects: 0
Study 21553144 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20116047 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral capsule/ventral striatum
Number of subjects: 6
Study 20116047 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study 20116047 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 6
Study 18683781 — intervention group
Group type: EXPERIMENTAL
Intervention: Energetic nutritional intervention (caloric supplementation for at least 2 weeks)
Number of subjects: 354
Study 15864805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular radiation therapy (IRT) with iridium (Ir)-192 (n = 60)
Number of subjects: 120